Solara Active Pharma Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Solara Active Pharma Sciences has confirmed there is no deviation or variation in the use of proceeds raised through its Rights Issue for the quarter ended June 30, 2025. The company received Rs. 149.49 crores on May 6, 2025 as the First Call money (Rs. 131.25 per partly paid share, including Rs. 3.50 face value and Rs. 127.75 premium) from 1,19,98,755 partly paid Rights Shares originally offered via Letter of Offer dated May 9, 2024. During the quarter, Rs. 138.27 crores was utilized — Rs. 115 crores towards repayment/pre-payment of borrowings and Rs. 23.27 crores for general corporate purposes. The remaining Rs. 11.22 crores (Rs. 0.26 crores in escrow and Rs. 10.96 crores in the monitoring account) is reserved for use in upcoming quarters. CRISIL Ratings is the appointed Monitoring Agency, and the Audit Committee reviewed the filing with no comments.
This is a routine regulatory compliance filing. The confirmation that funds are being deployed exactly as originally planned signals disciplined capital allocation and governance transparency, which is mildly reassuring for shareholders though largely neutral for the stock price.